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Technical Appendix
Results presented in the main text were obtained from the implementation of a Bayesian back-calculation model based on 
counts of new diagnoses of HIV and/or AIDS, stratified by CD4 count.
Back-Calculation
Back-calculation permits infection incidence to be estimated from time series of observed counts of disease endpoints and 
information on the distribution of the time from infection to the endpoint of interest. If time is divided into intervals (ti−1 , ti], 
i = 1, ..., I, in the discrete case, the method is based on the equation:
where μi is the expected number of endpoint events in the ith time interval, hj is the expected number of new infections in the 
jth time interval and fi-j represents the probability that the time between the infection and the endpoint is equal to i - j time 
intervals.
Back-calculation was first used to estimate the incidence of HIV using AIDS diagnoses as an endpoint,1 and the method has 
been subsequently extended, replacing AIDS diagnoses with HIV diagnoses.2;3 However, the occurrence of an HIV 
diagnosis, unlike AIDS, is not simply a function of infection progression. Diagnosis of HIV-infection follows the processes 
of infection transmission, infection progression, and presentation for, and acceptance of, testing. These processes interact in 
a complex way. Only by relating the observed data through a suitable back-calculation framework is it possible to unravel 
the effects of changes over calendar time in HIV testing patterns and in underlying HIV incidence. In the absence of direct 
knowledge of this shifting time to HIV diagnosis distribution, additional information is required to estimate both this 
distribution and infection incidence. Such information could be an indicator of recent infection or levels of some prognostic 
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marker at diagnosis.4;5 An earlier multi-state model was adapted and developed to represent the processes that underlie the 
observed HIV diagnosis data,5 which incorporated data on CD4 count at HIV diagnosis, and allowed the time-to-diagnosis 
to vary as infection progressed between disease stages defined by CD4 count (Figure 1).
New infections occur according to a (non-homogeneous) Poisson process with hi representing the expected number of new 
infections arriving in stage 1 during the interval (ti−1, ti]. At time ti, the expected number of individuals in each CD4 stage, k, 
k = 1, ..., 4, is given by Eki. Of these, a proportion dk(i+1) will be diagnosed in the next time interval (ti , ti+1]. Of those 
remaining undiagnosed, a proportion qk(k+1) will progress to the next CD4 stage in the subsequent time period. The time-to-
diagnosis distribution is, therefore, a complex function of the diagnosis probabilities and the disease progression parameters. 
The disease progression parameters are assumed fixed and known from an analysis of CASCADE data.6
As a result of the assumptions on the infection process, the number of arrivals into stages 6-9 (HIV diagnoses) and 5 (AIDS 
diagnoses) during the ith interval, are Poisson distributed with means μiHIV and μiAIDS respectively. These means are evaluated 
through a recursive process:
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Further technical detail can be found in a complementary paper [7].
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Figure 1: A multi-state model for population-level CD4 progression, leading to HIV and AIDS diagnoses.
The expected proportions of the HIV diagnoses in the ith interval that are attributable to individuals from CD4 state k = 1, . . 
. , 4, say rki, can then easily be found by
 rki=
E
k (i−1)
d
ki
μ
i
HIV
(2)
Data
Data are available on both the total number of HIV diagnoses and AIDS diagnoses for the entire history of the HIV 
epidemic in England & Wales. The first diagnosis occurred in mid-1979, so t0 was set to be the beginning of 1978, to allow 
sufficient incubation time for this initial diagnosis. Each time-step corresponds to a quarter year (three months). If an AIDS 
diagnosis occurred within one quarter of an initial HIV diagnosis, it was assumed that the diagnosis was of AIDS and not of 
HIV (and the individual contributed to the count at state 5 and not at state 9). Similarly, CD4 counts were assumed to be “at 
diagnosis” if they were measured within one quarter of the initial HIV diagnosis. This CD4 count data was available from 
1991 onwards, with 25% of diagnoses having CD4 data in 1991 rising to 91% in 2010.
Although both types of diagnosis (AIDS and HIV) were available throughout the entire history of the HIV epidemic, a 
diagnostic test for HIV became widely available only in 1984 and very few diagnoses were prior to this year, mostly due to 
the retrospective testing of archived specimens.
Bayesian Inference
A Bayesian framework for statistical inference was adopted for the ease with which it incorporates multiple datasets and can 
augment data with additional information on model parameters through prior probability distributions. Bayesian inference 
combines the information held in the priors with that held in the data, via the likelihood function, to produce posterior 
distributions for model parameters. These distributions form the basis of our inferences.
Likelihood
The overall likelihood arises as the product of the component likelihoods for the observed quarterly HIV diagnosis counts, 
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HIV ,  the quarterly AIDS diagnosis counts, X i
AIDS ,  and the quarterly CD4 count at diagnosis data Wi.
The likelihood for the diagnosis counts arise from the fact that these are independent Poisson random variables, i.e.
X
i
HIV∼ Po( μiHIV)
X
i
AIDS∼ Po( μiAIDS) .
 (3)
The CD4 count data are based on a sub-sample of the diagnoses of known size, Ni ≤ Xi, giving the number of these 
diagnoses that fall into each of the CD4 count strata. If Wki is the number of diagnoses in the ith interval with a CD4 count in 
CD4 state k, then Wi = (W1i ,..., W4i) follow a multinomial distribution
where ri is the vector of probabilities (r1i, ..., r4i) as defined in (2).
Priors
If both the infection incidence process, {hi : i = 1, …, I} and diagnosis process {dki : i = 1, …, I; k = 1, …, 4} are allowed to 
freely vary at each time, then the model is over-parameterised and estimation is difficult. Therefore, in the interests of model 
parsimony and identifiability, some smoothing of these processes is employed. This is done by assuming that they are both 
vary according to a random walk on the log- and the logistic- scales respectively. The random walks ensure that sudden 
jumps do not occur and that, for example, incidence in one quarter is correlated to incidence in the next quarter.  For 
example, in the case of incidence, if γi = log(hi), then
These random walks introduce variance parameters that control the range of likely values for the step size, e.g. σ γ,i
2  above.  
For the random walk on the diagnosis probabilities, this variance is held fixed over time whereas for the expected incidence, 
there is a breakpoint early on in the epidemic (in 1986) to represent the end of a period of initial early growth. These 
random-walk specifications for both the time-varying rates of infection and diagnosis describe the prior probability 
distributions for the majority of model parameters. All that is required beyond this is the specification of prior probability 
distributions for the variance parameters and the starting point for each random walk. All variance parameters are chosen to 
have reasonably uninformative priors, whereas the prior for the initial level of incidence is focused on very small values. 
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Because of the timing of the introduction of the diagnostic test for HIV infection, the random-walk process governing the 
diagnosis probabilities is only considered to have begun from 1985 onwards, once the use of an HIV diagnostic test was 
established and in widespread use. It is assumed that diagnosis levels in 1984 were scaled down from the levels of 1985 as 
the test was gradually introduced, so that d
ki
=c
1
d
ki
 where  t
i¿
 and ti correspond to times in 1984 and 1985 respectively. 
Furthermore, to allow for the diagnoses in the database that pre-date the 1984 introduction of the diagnostic test, a further 
proportional reduction in the diagnosis probabilities was allowed for to cover this period d
ki**
=c
0
c
1
d
ki
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corresponding to calendar times prior to 1984. The parameters c0 and c1 are given uninformative flat U[0, 1] priors. The 
priors for the initial (1985) levels of diagnosis are based on the results of an earlier study.8
Estimation
Evaluation of the posterior distributions used for inference was problematic due to their non-standard form, making them 
algebraically intractable. Their estimation was therefore made possible through Markov Chain-Monte Carlo (MCMC) 
simulation methods, which were implemented via the JAGS software,9 embedded into the statistical package R,10 using the 
RJAGS packages.11
Derived Quantities
Together with the disease progression probabilities, the estimated diagnosis probabilities at a particular time t specify a 
distribution for what we define to be a “snapshot” of the time-to-diagnosis interval i.e. the interval that would be observed 
were the probabilities of diagnosis held fixed at the time of the snapshot.
Furthermore, in equation (1), we calculate Eki the expected numbers of people in each of the CD4 count states k at the end of 
the ith time interval. These quantities allow us to estimate the undiagnosed prevalence over time and the time-varying 
distribution of the undiagnosed prevalence across the CD4 count states. Further detail on how to derive these posterior 
distributions as well as how the calculate the snapshot time-to-diagnosis distributions can be found in [7].
Results
HIV Incidence
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Figure 1 (main paper) shows summaries of the posterior distributions for the number of new infections for each year, 2001-
2010. These summaries consist of posterior medians and the corresponding 95% credible intervals. To detect any difference 
between the levels of incidence in each of the years, and, therefore, to provide evidence of any possible trend, we use 
posterior probabilities, pij, that incidence in year i is greater than incidence in year j. These can be readily estimated from the 
MCMC simulation. Values of  pij that lie close to 0 or 1 provide evidence that there is a significant difference between the 
incidence in the two years.
For the years under study, the most significant of these posterior probabilities was the one corresponding to the years 2001 
and 2004, which stated that incidence was greater in 2004 with probability 0.89. This is not considered to be particularly 
significant deviation in incidence between the two years. For the last three years, there is much weaker evidence of any 
difference to any of the other years, as can be expected from the widening credible intervals attached to the incidence over 
this period. For instance the posterior probabilities p2010,j range from 0.31 (2004) to 0.54 (2001).
Goodness-of-fit
The plots in Figure 2 show the ability of the model to predict the last ten years-worth of quarterly HIV and AIDS at HIV 
diagnosis counts, as well as the observed distribution of CD4 counts at diagnosis, conditional upon the size of the sample.
The dashed lines represent 95% predictive intervals under the model. As can be seen, these contain almost all (>99%) of all 
the data points, highlighting the model's suitability for handling such data.
Sensitivity to the Choice of the Incubation Period Distribution
An underlying assumption in the model is that the mean incubation period to AIDS is taken to be 8·6 years, as estimated 
from a longitudinal analysis of individual CD4 count histories from the CASCADE collaboration.12 Longer incubation 
periods have been quoted in literature on the basis of similar types of data,13,14 with the discrepancy attributable to 
differences in the assumed distribution of CD4 counts at, or shortly after, seroconversion. If a slower infection progression 
is assumed, such as the 11 years obtained by a survival analysis,12 this would simply serve to further smooth the infection 
incidence curve and not lead to any changes to the trend in HIV incidence, our primary focus. Preliminary work has also 
suggested our conclusions would not be substantially altered if the model is extended to account for the known differences 
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in HIV progression associated with age at infection.
7
8Figure 2: Goodness-of-fit plots relating the data (red +'s) to the predictive distribution under our model, represented by its  
median (solid black line) and bounds of the 95% credibility interval (dotted line). Plots are arranged so that the HIV  
diagnoses are in the top left, the AIDS diagnoses are top right, and the bottom four plots are the CD4 count-at-diagnosis  
data.
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